Long-acting GHRH analogue with an albumin-binding DAC group
PRODUCT PROFILE
CJC-1295 DAC
Price range: £32.99 through £39.99
CJC-1295 DAC is long-acting ghrh analogue with an albumin-binding dac group. Researchers examine it in relation to sustained elevation of endogenous gh and igf-1 while retaining pituitary pulsatility.
Why it is distinct
Its albumin-binding extension creates sustained exposure, unlike CJC-1295 No DAC or sermorelin.
- Evidence stageEarly human evidence
- AvailabilityAvailable · select size for stock
- Batch recordOpen COA
- DispatchConfirmed at checkout
SUGGESTED ADD-ONS
Useful additions, clearly shown.
Suggestions are organised by vial format and catalogue context. They are not combined-use guidance or personal-use advice.
-
Specification review
Bacteriostatic Water
Price range: £4.49 through £8.9910 mL | 3 mLBatch file pendingA laboratory supply with two volume variants, not a peptide or biologically active comparison material.
Available · select size for stockAdd to basket This product has multiple variants. The options may be chosen on the product page -
Established clinical evidence
Tesamorelin
£52.99Batch COA availableIt is the GHRH analogue in this catalogue with an authorised indication and outcome trials for a defined…
Available · 50 in stockAdd to basket -
Early human evidence
Ipamorelin
Price range: £34.99 through £54.995 mgBatch COA availableA ghrelin-receptor secretagogue—not a GHRH analogue—and generally discussed as more selective than older GHRPs.
Available · select size for stockAdd to basket This product has multiple variants. The options may be chosen on the product page
PRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
CJC-1295 DAC is long-acting ghrh analogue with an albumin-binding dac group. Researchers examine it in relation to sustained elevation of endogenous gh and igf-1 while retaining pituitary pulsatility.
Research focus+
Researchers study its effects on growth hormone and IGF-1. The DAC attachment makes it last much longer than CJC-1295 No DAC.
How the mechanism differs+
Activates GHRH receptors and covalently associates with circulating albumin, extending exposure for days.
Evidence and limitations+
Randomised early human pharmacology demonstrated prolonged GH and IGF-1 increases; clinical outcome evidence remains limited.
Testing and batch documentation+
Verified batch documents are available for review.
RESEARCH PROFILE
Understand the distinction.
Researchers study its effects on growth hormone and IGF-1. The DAC attachment makes it last much longer than CJC-1295 No DAC.
Activates GHRH receptors and covalently associates with circulating albumin, extending exposure for days.
Its albumin-binding extension creates sustained exposure, unlike CJC-1295 No DAC or sermorelin.
Randomised early human pharmacology demonstrated prolonged GH and IGF-1 increases; clinical outcome evidence remains limited.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Early human evidence
CJC-1295 No DAC
Price range: £25.99 through £32.995 mgBatch COA availableShort-duration GHRH signalling, in contrast with albumin-bound, long-acting CJC-1295 DAC.
UnavailableAsk about availability This product has multiple variants. The options may be chosen on the product page -
Established
Sermorelin
£49.005 mgBatch COA availableClosest to the natural active GHRH sequence and shorter acting than tesamorelin or CJC-1295 DAC.
UnavailableAsk about availability -
Early human evidence
GHRP-2
£44.005 mgBatch COA availableTypically characterised as a strong GH secretagogue with less appetite emphasis than GHRP-6.
UnavailableAsk about availability -
Experimental
PEG-MGF
£61.002 mgBatch COA availableA modified splice-variant fragment rather than a direct full IGF-1 receptor analogue.
UnavailableAsk about availability